. "17" . "15110" . . "Cytogenetick\u00E9 a molekul\u00E1rn\u011B biologick\u00E9 markery v onkologii solidn\u00EDch n\u00E1dor\u016F a hematologick\u00FDch malignit"@cs . "Cytogenetika a molekul\u00E1rn\u00ED genetika se staly ned\u00EDlnou sou\u010D\u00E1st\u00ED diagnostick\u00FDch a prognostick\u00FDch metod v onkologii solidn\u00EDch n\u00E1dor\u016F ai hematologick\u00FDch malignit. Jejich v\u00FDznam, potvrzen\u00FD na velk\u00FDch souborech nemocn\u00FDch, se stal rutinn\u00ED sou\u010D\u00E1st\u00ED klinick\u00E9 diagnostiky a v n\u011Bkter\u00FDch p\u0159\u00EDpadech i klasifika\u010Dn\u00EDch krit\u00E9ri\u00ED. N\u00E1lezy genetick\u00FDch a cytogenetick\u00FDch zm\u011Bn se u leuk\u00E9mi\u00ED a solidn\u00EDch n\u00E1dor\u016F pohybuj\u00ED v rozmez\u00ED 60-90% a zahrnuj\u00ED i zcela specifick\u00E9 zm\u011Bny, kter\u00E9 lze vyu\u017E\u00EDt p\u0159i identifikaci rizikov\u00FDch jedinc\u016F, diagnostice, k ur\u010Den\u00ED progn\u00F3zy, predikci odpov\u011Bdi na specifickou l\u00E9\u010Dbu, \u010Di moniitorov\u00E1n\u00ED aktivity procesu. Na konkr\u00E9tn\u00EDch p\u0159\u00EDkladech t\u0159\u00ED n\u00E1dor\u016F (karcinom prsu, chronick\u00E1 myeloidn\u00ED leuk\u00E9mie a akutn\u00ED promyelocyt\u00E1rn\u00ED leuk\u00E9mie) upozor\u0148ujeme na v\u00FDznam genetick\u00FDch studi\u00ED pro diagnostiku, progn\u00F3zu a l\u00E9\u010Dbu nemocn\u00FDch se solidn\u00EDmi n\u00E1dory i hematologick\u00FDmi malignitami v kontextu medic\u00EDnsk\u00E9m a ekonomick\u00E9m." . "Cytogenetics and molecular biological markers in oncology and hematooncology"@en . "Cytogenetick\u00E9 a molekul\u00E1rn\u011B biologick\u00E9 markery v onkologii solidn\u00EDch n\u00E1dor\u016F a hematologick\u00FDch malignit"@cs . "6"^^ . "Cytogenetics and molecular genetics become an essential part of diagnostcs and prognostification in oncology of both the solid tumors and hematological malignancies. Their significanse has been confirmed in large multicentric prospective or retrospective studies and they were successfully incorporated in routine clinical diagnostics and patient stratification. Cytogenetic and/or genetic alterations were detected in 60-90% of leukemias and solid tumors, and those involve specific changes applicable for identification of high-risk individuals, disease prognostification, prediction of therapy response or monitoring of disease activity. In this paper we underline importance of those markers in diagnostics, prognostification and prediction of therapy response in patients suffering from breast cancer, chronic myeloid leukemia and acute promyelocytic leukemia within the frames of medical and economical consequences."@en . "Cytogenetics and molecular biological markers in oncology and hematooncology"@en . "Jaro\u0161ov\u00E1, Marie" . "Cytogenetick\u00E9 a molekul\u00E1rn\u011B biologick\u00E9 markery v onkologii solidn\u00EDch n\u00E1dor\u016F a hematologick\u00FDch malignit" . . "Papaj\u00EDk, Tom\u00E1\u0161" . "Hajd\u00FAch, Mari\u00E1n" . "6"^^ . . "6"^^ . "breast cancer; chronic myeloid leukemia; acute promyelocytic leukemia; ERBB2; bcr-abl; PML-RAR_; trastuzumab; imatinib mesylate; all-trans-retinoid acid"@en . "[865BEF51839D]" . . "CZ - \u010Cesk\u00E1 republika" . . . "RIV/61989592:15110/04:00006057!RIV09-MZ0-15110___" . "0862-495X" . . "Cytogenetick\u00E9 a molekul\u00E1rn\u011B biologick\u00E9 markery v onkologii solidn\u00EDch n\u00E1dor\u016F a hematologick\u00FDch malignit" . . "S1" . . . . . . . . "RIV/61989592:15110/04:00006057" . . "P(NC7490), P(NC7495), P(NC7506), Z(MSM 151100001)" . "559199" . . . . . "Cytogenetika a molekul\u00E1rn\u00ED genetika se staly ned\u00EDlnou sou\u010D\u00E1st\u00ED diagnostick\u00FDch a prognostick\u00FDch metod v onkologii solidn\u00EDch n\u00E1dor\u016F ai hematologick\u00FDch malignit. Jejich v\u00FDznam, potvrzen\u00FD na velk\u00FDch souborech nemocn\u00FDch, se stal rutinn\u00ED sou\u010D\u00E1st\u00ED klinick\u00E9 diagnostiky a v n\u011Bkter\u00FDch p\u0159\u00EDpadech i klasifika\u010Dn\u00EDch krit\u00E9ri\u00ED. N\u00E1lezy genetick\u00FDch a cytogenetick\u00FDch zm\u011Bn se u leuk\u00E9mi\u00ED a solidn\u00EDch n\u00E1dor\u016F pohybuj\u00ED v rozmez\u00ED 60-90% a zahrnuj\u00ED i zcela specifick\u00E9 zm\u011Bny, kter\u00E9 lze vyu\u017E\u00EDt p\u0159i identifikaci rizikov\u00FDch jedinc\u016F, diagnostice, k ur\u010Den\u00ED progn\u00F3zy, predikci odpov\u011Bdi na specifickou l\u00E9\u010Dbu, \u010Di moniitorov\u00E1n\u00ED aktivity procesu. Na konkr\u00E9tn\u00EDch p\u0159\u00EDkladech t\u0159\u00ED n\u00E1dor\u016F (karcinom prsu, chronick\u00E1 myeloidn\u00ED leuk\u00E9mie a akutn\u00ED promyelocyt\u00E1rn\u00ED leuk\u00E9mie) upozor\u0148ujeme na v\u00FDznam genetick\u00FDch studi\u00ED pro diagnostiku, progn\u00F3zu a l\u00E9\u010Dbu nemocn\u00FDch se solidn\u00EDmi n\u00E1dory i hematologick\u00FDmi malignitami v kontextu medic\u00EDnsk\u00E9m a ekonomick\u00E9m."@cs . . . . . . . "Cwiertka, Karel" . "Klinick\u00E1 onkologie" . . . "\u0160pa\u010Dkov\u00E1, Kate\u0159ina" . "Trojanec, Radek" . .